James Kublin, MD, MPH, Executive Director of HVTN, Visits Harare

hvtn site visitHIV Vaccine Trials Network (HVTN) Executive Director, James Kublin, MD, MPH, lead a one-day training on 3 October 2014, in Harare, aimed at orienting Zimbabwe national regulators to the work of the HVTN, the P5 Initiative in Southern Africa, and Phase I clinical trials the network is planning for implementation in the region.  The P5 Initiative is a response to the RV144 HIV vaccine trial in Thailand that was the first study to show efficacy in preventing HIV infection.  The initiative aims to extend and confirm these findings in other geographical regions.

UZCHS-CTU is currently working with the HVTN in preparation to implement the first HIV-vaccine study in Zimbabwe, HVTN 107, projected to begin in spring 2015 at Seke South CRS.

No comments yet.

Leave a Reply